Merus

Business

Merus stock target raised, holds Buy rating on oncology drug potential By Investing.com

On Wednesday, Citi maintained a Buy rating on Merus N.V. (NASDAQ:) and raised its stock price target to $93 from…

Read More »
Back to top button